DB:2LB

Stock Analysis Report

Executive Summary

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells.


Snowflake Analysis

Flawless balance sheet and slightly overvalued.

Share Price & News

How has Iovance Biotherapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 2LB's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

19.5%

2LB

11.2%

DE Biotechs

7.3%

DE Market


1 Year Return

232.2%

2LB

-5.1%

DE Biotechs

-17.7%

DE Market

Return vs Industry: 2LB exceeded the German Biotechs industry which returned -5.1% over the past year.

Return vs Market: 2LB exceeded the German Market which returned -17.5% over the past year.


Shareholder returns

2LBIndustryMarket
7 Day19.5%11.2%7.3%
30 Day2.2%-5.3%-17.9%
90 Day13.7%-21.9%-25.8%
1 Year232.2%232.2%-4.9%-5.1%-15.1%-17.7%
3 Year317.2%317.2%17.7%16.5%-18.7%-25.6%
5 Year129.9%129.9%-5.1%-7.5%-17.7%-29.0%

Price Volatility Vs. Market

How volatile is Iovance Biotherapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Iovance Biotherapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 2LB (€28.2) is trading below our estimate of fair value (€81.65)

Significantly Below Fair Value: 2LB is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 2LB is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 2LB is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 2LB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 2LB is overvalued based on its PB Ratio (13.6x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Iovance Biotherapeutics forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

37.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2LB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 2LB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 2LB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if 2LB's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if 2LB's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 2LB's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Iovance Biotherapeutics performed over the past 5 years?

-36.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 2LB is currently unprofitable.

Growing Profit Margin: 2LB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 2LB is unprofitable, and losses have increased over the past 5 years at a rate of -36.7% per year.

Accelerating Growth: Unable to compare 2LB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2LB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: 2LB has a negative Return on Equity (-66.08%), as it is currently unprofitable.


Next Steps

Financial Health

How is Iovance Biotherapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: 2LB's short term assets ($316.5M) exceed its short term liabilities ($39.1M).

Long Term Liabilities: 2LB's short term assets ($316.5M) exceed its long term liabilities ($6.6M).


Debt to Equity History and Analysis

Debt Level: 2LB is debt free.

Reducing Debt: 2LB had no debt 5 years ago.


Balance Sheet

Inventory Level: 2LB has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 2LB's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 2LB has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 2LB has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of -45.6% each year.


Next Steps

Dividend

What is Iovance Biotherapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 2LB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 2LB's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 2LB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 2LB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 2LB's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.2yrs

Average management tenure


CEO

Maria Fardis (51yo)

3.75s

Tenure

US$9,394,600

Compensation

Dr. Maria Fardis, PhD, MBA, has been the Chief Executive Officer and President of Iovance Biotherapeutics, Inc. since June 1, 2016. Previously, Dr. Fardis held a number of key scientific and management rol ...


CEO Compensation Analysis

Compensation vs Market: Maria's total compensation ($USD9.39M) is above average for companies of similar size in the German market ($USD3.71M).

Compensation vs Earnings: Maria's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Maria Fardis
CEO, President & Director3.75yrsUS$9.39m0.24% $8.8m
Timothy Morris
CFO, Principal Accounting Officer2.58yrsUS$603.00kno data
Frederick Vogt
General Counsel2.67yrsUS$502.50kno data
Sara Pellegrino
Vice President of Investor Relations & Public Relationsno datano datano data
Howard Johnson
Senior Vice President of Corporate Development4.58yrsno datano data
Friedrich Graf Finckenstein
Chief Medical Officer0.67yrno datano data
Kelly DiTrapani
Vice President of Medical Affairsno datano datano data
Elma Hawkins
Advisor to the Board3.75yrsUS$3.18mno data

3.2yrs

Average Tenure

57yo

Average Age

Experienced Management: 2LB's management team is considered experienced (3.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Maria Fardis
CEO, President & Director3.75yrsUS$9.39m0.24% $8.8m
Mario Sznol
Member of Scientific Advisory Boardno datano datano data
Merrill McPeak
Independent Director8.67yrsUS$561.43k0.36% $13.2m
Michael Weiser
Independent Director2yrsUS$1.33m0.10% $3.8m
Jeffrey Weber
Member of Scientific Advisory Boardno datano datano data
Patrick Hwu
Member of Scientific Advisory Boardno datano datano data
Ryan Maynard
Independent Director5yrsUS$546.43kno data
Iain Dukes
Chairman of the Board3.58yrsUS$1.05m0.0095% $348.2k
James Mulé
Member of Scientific Advisory Boardno datano datano data
Cassian Yee
Member of Scientific Advisory Boardno datano datano data

3.8yrs

Average Tenure

58.5yo

Average Age

Experienced Board: 2LB's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.8%.


Top Shareholders

Company Information

Iovance Biotherapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Iovance Biotherapeutics, Inc.
  • Ticker: 2LB
  • Exchange: DB
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$4.068b
  • Listing Market Cap: US$3.669b
  • Shares outstanding: 126.50m
  • Website: https://www.iovance.com

Number of Employees


Location

  • Iovance Biotherapeutics, Inc.
  • 999 Skyway Road
  • Suite 150
  • San Carlos
  • California
  • 94070
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IOVANasdaqGM (Nasdaq Global Market)YesCommon SharesUSUSDJun 2008
2LBDB (Deutsche Boerse AG)YesCommon SharesDEEURJun 2008
0JDKLSE (London Stock Exchange)YesCommon SharesGBUSDJun 2008

Biography

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company’s lead product candidates include lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma; and LN-145 for the treatment of metastatic cervical cancer. It is also developing tumor infiltrating lymphocytes (TIL) and peripheral blood lymphocyte therapies for the treatment of squamous cell carcinoma of the head and neck, non-small cell lung cancer, and chronic lymphocytic leukemia through its sponsored trials, as well as in other oncology indications through collaborations. Iovance Biotherapeutics, Inc. has collaboration agreements with Moffitt, M.D. Anderson Cancer Center, Ohio State University, and MedImmune; and research collaboration with Cellectis S.A. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/29 23:24
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.